Publications by authors named "Jose Francisco Suarez-Novo"
Darolutamide significantly prolonged metastasis-free survival (MFS) versus placebo in the Phase III ARAMIS study. We analyzed outcomes in Spanish participants in ARAMIS. Patients with high-risk nonmetastatic castration-resistant prostate cancer were randomized 2:1 to darolutamide 600 mg twice daily or placebo, plus androgen-deprivation therapy.
View Article and Find Full Text PDFObjective: To describe the clinical findings in patients with incidental prostatic amyloidosis.
Patients And Methods: Retrospective search in the database of the Department of Pathology, Hospital de Bellvitge, for prostate specimens with amyloid. Congo red and immunohistochemical staining of the sections.
Introduction: Varicocele is the most common cause of male infertility and the standard treatment is varicocelectomy. Having recently started performing microsurgical varicocelectomy (MV) in our centre, the objective of this study is to determine the differences in clinical outcomes and laboratory findings between MV and the conventional varicocelectomy (CV).
Material And Methods: This is a comparative study between MV and CV in our centre between 01/2013 and 12/2016.
Intraethnic variation in steroid-5-alpha-reductase polymorphismsin prostate cancer patients: a potential factor implicated in 5-alpha-reductase inhibitor treatment.
J Genet
June 2015
Article Synopsis
- - The study investigates the impact of genetic variations in specific androgen metabolism genes (CYP17A1, SRD5A1, and SRD5A2) on prostate cancer risk and characteristics among Spanish patients.
- - Researchers analyzed 494 patients with nonmetastatic localized prostate cancer, focusing on 32 single nucleotide polymorphisms (SNPs) and found significant associations between certain SNPs in the SRD5A1 gene and higher prostate-specific antigen levels at diagnosis.
- - Results indicated that nonhomozygous patients for a specific haplotype demonstrated a significantly greater risk of larger tumor size and higher Gleason scores, suggesting that SNPs in SRD5A1 may influence the severity of
Background: Besides serum levels of PSA, there is a lack of prostate cancer specific biomarkers. It is need to develop new biological markers associated with the tumor behavior which would be valuable to better individualize treatment. The aim of this study was to elucidate the relationship between single nucleotide polymorphisms (SNPs) in genes involved in DNA repair and prostate cancer progression.
View Article and Find Full Text PDFObjective: To evaluate the influence of obesity in the results of percutaneous nephrolithotomy (PCNL) in terms of efficacy and safety and to evaluate other aspects such as fluoroscopy time, radiation exposure, total operative time, hemoglobin loss, hospital stay, and the need of auxiliary procedures.
Materials And Methods: We evaluated prospectively all the PCNLs performed at our institution between 2011 and 2012. A series of perioperative and postoperative details were recorded in our database.
Polymorphisms in DNA-repair genes in a cohort of prostate cancer patients from different areas in Spain: heterogeneity between populations as a confounding factor in association studies.
PLoS One
March 2014
Background: Differences in the distribution of genotypes between individuals of the same ethnicity are an important confounder factor commonly undervalued in typical association studies conducted in radiogenomics.
Objective: To evaluate the genotypic distribution of SNPs in a wide set of Spanish prostate cancer patients for determine the homogeneity of the population and to disclose potential bias.
Design Setting And Participants: A total of 601 prostate cancer patients from Andalusia, Basque Country, Canary and Catalonia were genotyped for 10 SNPs located in 6 different genes associated to DNA repair: XRCC1 (rs25487, rs25489, rs1799782), ERCC2 (rs13181), ERCC1 (rs11615), LIG4 (rs1805388, rs1805386), ATM (rs17503908, rs1800057) and P53 (rs1042522).